TargetBeta
KIF18A
kinesin family member 18A · also DKFZP434G2226, PPP1R99 · Kinesins
2 programs in company-led studies act on KIF18A, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| KIF18A Inhibitor ATX-295rule | Accent Therapeutics | phase 2 | 11 running | – | NCIt |
| KIF18A Inhibitor MEN2501rule | Menarini Group | phase 1 | 11 running | – | NCIt |
Conditions their studies are in
- Ovarian Neoplasms, 2 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 30, 2027KIF18A Inhibitor ATX-295 · Accent Therapeutics · phase 2 · NCT06799065
- Dec 2, 2027KIF18A Inhibitor MEN2501 · Menarini Group · phase 1 · NCT07226427
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.